Literature DB >> 9718352

Dihydropyrimidinase deficiency: structural organization, chromosomal localization, and mutation analysis of the human dihydropyrimidinase gene.

N Hamajima1, M Kouwaki, P Vreken, K Matsuda, S Sumi, M Imaeda, S Ohba, K Kidouchi, M Nonaka, M Sasaki, N Tamaki, Y Endo, R De Abreu, J Rotteveel, A van Kuilenburg, A van Gennip, H Togari, Y Wada.   

Abstract

Dihydropyrimidinase (DHP) deficiency (MIM 222748) is characterized by dihydropyrimidinuria and is associated with a variable clinical phenotype. This disease might be associated with a risk of 5-fluorouracil toxicity, although no cases have been reported. We present here both the molecular characterization of the human DHP gene and, for the first time, the mutations causing DHP deficiency. The human DHP gene spans >80 kb and consists of 10 exons. It has been assigned to 8q22, by FISH. We performed mutation analysis of genomic DNA in one symptomatic and five asymptomatic individuals presenting with dihydropyrimidinuria. We identified one frameshift mutation and five missense mutations. Two related Japanese adult subjects were homozygous for the Q334R substitution, whereas two other, unrelated Japanese infant subjects were heterozygous for the same mutation, but this mutation is not common in the Japanese population. A Caucasian pediatric patient exhibiting epileptic attacks, dysmorphic features, and severe developmental delay was homozygous for W360R. Using a eukaryotic expression system, we showed that all mutations reduced enzyme activity significantly, indicating that these are crucial DHP deficiency-causing mutations. There was no significant difference, in residual activity, between mutations observed in the symptomatic and those observed in the asymptomatic individuals.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9718352      PMCID: PMC1377410          DOI: 10.1086/302022

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  12 in total

1.  Divergent functions through alternative splicing: the Drosophila CRMP gene in pyrimidine metabolism, brain, and behavior.

Authors:  Deanna H Morris; Josh Dubnau; Jae H Park; John M Rawls
Journal:  Genetics       Date:  2012-05-29       Impact factor: 4.562

2.  Analysis of pyrimidine catabolism in Drosophila melanogaster using epistatic interactions with mutations of pyrimidine biosynthesis and beta-alanine metabolism.

Authors:  John M Rawls
Journal:  Genetics       Date:  2005-12-15       Impact factor: 4.562

3.  Physiologically based pharmacokinetic modelling of the three-step metabolism of pyrimidine using C-uracil as an in vivo probe.

Authors:  Suminobu Ito; Takeshi Kawamura; Makoto Inada; Yoshiharu Inoue; Yukihiro Hirao; Toshihisa Koga; Jun-ichi Kunizaki; Takefumi Shimizu; Hitoshi Sato
Journal:  Br J Clin Pharmacol       Date:  2005-12       Impact factor: 4.335

4.  Dihydropyrimidinase deficiency: the first feline case of dihydropyrimidinuria with clinical and molecular findings.

Authors:  Hye-Sook Chang; Takako Shibata; Satoshi Arai; Chunhua Zhang; Akira Yabuki; Sawane Mitani; Takashi Higo; Kazuhiro Sunagawa; Keijiro Mizukami; Osamu Yamato
Journal:  JIMD Rep       Date:  2012-03-29

Review 5.  Germline oncopharmacogenetics, a promising field in cancer therapy.

Authors:  Chiara Pesenti; Milena Gusella; Silvia M Sirchia; Monica Miozzo
Journal:  Cell Oncol (Dordr)       Date:  2015-01-09       Impact factor: 6.730

6.  A novel stop-gain mutation in DPYS gene causing Dihidropyrimidinase deficiency, a case report.

Authors:  Malihe Mirzaei; Arghavan Kavosi; Mahboobeh Sharifzadeh; Ghazale Mahjoub; Mohammad Ali Faghihi; Parham Habibzadeh; Majid Yavarian
Journal:  BMC Med Genet       Date:  2020-06-29       Impact factor: 2.103

7.  Assessment of coding region variants in Kuwaiti population: implications for medical genetics and population genomics.

Authors:  Sumi Elsa John; Dinu Antony; Muthukrishnan Eaaswarkhanth; Prashantha Hebbar; Arshad Mohamed Channanath; Daisy Thomas; Sriraman Devarajan; Jaakko Tuomilehto; Fahd Al-Mulla; Osama Alsmadi; Thangavel Alphonse Thanaraj
Journal:  Sci Rep       Date:  2018-11-08       Impact factor: 4.379

8.  Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity.

Authors:  A Loganayagam; M Arenas Hernandez; A Corrigan; L Fairbanks; C M Lewis; P Harper; N Maisey; P Ross; J D Sanderson; A M Marinaki
Journal:  Br J Cancer       Date:  2013-06-04       Impact factor: 7.640

9.  Genetic polymorphisms of dihydropyrimidinase in a Japanese patient with capecitabine-induced toxicity.

Authors:  Masahiro Hiratsuka; Hiroshi Yamashita; Fumika Akai; Hiroki Hosono; Eiji Hishinuma; Noriyasu Hirasawa; Takahiro Mori
Journal:  PLoS One       Date:  2015-04-27       Impact factor: 3.240

10.  Altered Pre-mRNA Splicing Caused by a Novel Intronic Mutation c.1443+5G>A in the Dihydropyrimidinase (DPYS) Gene.

Authors:  Yoko Nakajima; Judith Meijer; Chunhua Zhang; Xu Wang; Tomomi Kondo; Tetsuya Ito; Doreen Dobritzsch; André B P Van Kuilenburg
Journal:  Int J Mol Sci       Date:  2016-01-12       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.